National Institute for Health and Care Excellence9 小时
In consultation: Guidance and quality standards
Natalizumab (originator and biosimilar) for treating highly active relapsing–remitting multiple sclerosis after disease-modifying therapy [ID6369] Draft guidance Technology appraisal guidance 2 April ...